US Stock Market News | LaiLi Financial Raises Target Price to $26, Novavax Pharmaceuticals Rises Over 3%
I'm PortAI, I can summarize articles.
On Thursday, Novavax Pharmaceuticals fluctuated and rose more than 5% at one point, and as of the time of publication, it rose over 3% to $13.08. On the news front, Riley Financial analyst Mayank Mamtani maintained a "buy" rating on Novavax Pharmaceuticals and raised the target price from $23 to $26
On Thursday, Novavax (NVAX.US) fluctuated and rose more than 5% at one point, and as of the time of publication, it has risen more than 3% to $13.08. On the news front, Riley Financial analyst Mayank Mamtani maintained a "buy" rating on Novavax and raised the target price from $23 to $26